SCHEMBL4678065

SCHEMBL4678065

COCc1cc(C(=O)C=C(O)c2nc[nH]n2)cn1Cc1ccc(C)cc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.33
BRD4 O60885 1/20 0.32
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
KLKB1 P03952 3/20 0.31
CNR2 P34972 2/20 0.31
CNR1 P21554 1/20 0.31
P2RY14 Q15391 3/20 0.31
MAPK10 P53779 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MAPT P10636 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90B1 P14625 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899407 0.91 USP2 (0.39) ALDH1A1BRD4MAPK10NPC1RAB9A
SCHEMBL4672046 0.86 ALDH1A1 (0.33) ALDH1A1LMNA
SCHEMBL4673720 0.86 ALDH1A1 (0.35) ALDH1A1LMNATP53KLKB1P2RY14
SCHEMBL4675654 0.85 MCL1 (0.39) ALDH1A1LMNABRD4CNR2CNR1
SCHEMBL4673403 0.83 BRD4 (0.35) ALDH1A1BRD4PPARGSMN1; SMN2HDAC6
SCHEMBL4675256 0.82 KDM4E (0.36) ALDH1A1LMNABRD4CNR2P2RY14
SCHEMBL4676801 0.82 LMNA (0.42) ALDH1A1LMNATP53BRD4P2RY14
SCHEMBL4675068 0.82 SMN1; SMN2 (0.41) ALDH1A1LMNAMAPK10NPC1RAB9A
SCHEMBL4674631 0.80 TDP1 (0.35) ALDH1A1LMNATP53BRD4P2RY14
SCHEMBL4677748 0.80 ALKBH1 (0.35) ALDH1A1LMNAMAPK10RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885LMNA 659/4885TP53 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.